SOURCE: Market Pulse

March 03, 2006 08:35 ET

Market Pulse Breaking News Alert for Friday, March 3, 2006: DNAG -- DNAPrint Genomics Enters Into Sponsored Research Agreement With Massachusetts College of Pharmacy and Health Sciences!

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Market Pulse.

ATLANTA, GA -- (MARKET WIRE) -- March 3, 2006 -- Market Pulse News Alert for this AM, Stocks to Watch are: DNAPrint Genomics, Inc. (OTC BB: DNAG), Google Inc. (NASDAQ: GOOG), Finisar Corp. (NASDAQ: FNSR) and Advanced Micro Devices Inc. (NYSE: AMD).

Investors need to be watching DNAPrint Genomics, Inc. (OTC BB: DNAG) this AM! DNAPrint is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology, and consumer genetic tests. DNAPrint's family of products for the law enforcement forensics and consumer markets include DNAWitness™, RETINOME™ (a predictive test for inferring eye color from a DNA sample), ANCESTRYbyDNA™, and EURO-DNA™. DNAPrint's management sees exciting growth opportunity in these markets to introduce and sell their novel products and services. DNAG has had several excellent news announcements out lately and one again before today's opening bell announcing that it has entered into a research sponsorship agreement with the Massachusetts College of Pharmacy and Health Sciences for the potential development of Ritalin™-like compounds as possible medications! This could be great news for investors!

DNAPrint Genomics, Inc. (OTC BB: DNAG) today announced that it has entered into a Research Sponsorship Agreement with the Massachusetts College of Pharmacy and Health Sciences for the potential development of Ritalin™-like compounds as possible medications for drug abuse, attention deficit hyperactivity disorder (ADHD) and depression. According to the National Institute of Mental Health, between 3 and 5 percent of children have ADHD, or approximately 2 million children in the United States.

The research will be conducted under the supervision of Dr. Mark Froimowitz, a researcher at the Boston-based College, who recently licensed the compounds to DNAPrint Genomics. The compounds are analogs of Ritalin™, a well-known drug used for treatment of ADHD and designed specifically to take effect slowly but last longer, thus reducing their potential for abuse and a patient's required daily dosage.

DNAPrint Chairman and Chief Medical Officer Hector J. Gomez, M.D., Ph.D., who also heads the clinical development for the Company's newly formed subsidiary, DNAPrint Pharmaceuticals, Inc., said his staff and Dr. Froimowitz will be working together closely to develop "theranostic" test/drug combinations based on the compounds designed to insure that patients receive the appropriate medicine and proper dosage based on a patient's genetic constitution. Theranostic test/drug combinations are designed to reduce efficacy and side effects problems associated with conventional drug treatments.

"These Ritalin-like compounds present an ideal opportunity for our goal to develop products for personalized medicine," Dr. Gomez stated. "DNAPrint's capabilities in genomics and the College's expertise in pharmaceuticals represent a powerful synergy in the field of theranostic drug research."

According to Dr. Froimowitz, Research Professor of Chemistry at the Massachusetts College of Pharmacy and Health Sciences, "These compounds have a number of desirable properties and possible therapeutic indications. The possibility of linking their clinical use to patient genomics represents the future of drug development."

"Many researchers believe that a strong link exists between drug addiction, ADHD and depression. There is a tremendous variation, however, across patient populations, with respect to drug response for the therapies used to treat these disorders," said Richard Gabriel, Chief Executive Officer and President of DNAPrint Genomics, Inc. "In fact, the National Institute of Drug Abuse has selected one of Dr. Froimowitz's compounds for their pre-clinical drug addiction development program. We will be supplying purified compounds to NIDA for further development."

About DNAPrint Genomics, Inc.

DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Pre-clinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to better design actual trials and are targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS™, RETINOME™, ANCESTRYbyDNA™ and EURO-DNA™. DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

About MCPHS

Founded in 1823, Massachusetts College of Pharmacy and Health Sciences (www.mcphs.edu) is a private coeducational college offering graduate, professional and undergraduate degrees in pharmacy and health sciences. With campuses in Boston and Worcester, Massachusetts and Manchester, New Hampshire, MCPHS is the oldest institution of higher education in the City of Boston and its pharmacy program is the second oldest in the U.S. Professional or undergraduate degrees are offered in pharmacy, nursing, physician assistant studies, dental hygiene, radiologic sciences, environmental science, health psychology, chemistry, and premedical and health studies. Graduate programs are offered in drug regulatory affairs/health policy, drug discovery and development, pharmacy systems administration, pharmaceutical sciences, medicinal chemistry, and pharmacology. The College enrolls approximately 2,800 students, who are drawn from 32 states and 30 foreign countries, and employs more than 300 faculty and staff.

MCPHS is accredited by the New England Association of Schools and Colleges and has received degree granting authority from the Great and General Court of Massachusetts and the New Hampshire Postsecondary Education Commission.

Stocks in the news and acting well as of late include: Google Inc. (NASDAQ: GOOG), Finisar Corp. (NASDAQ: FNSR) and Advanced Micro Devices Inc. (NYSE: AMD).

Information contained herein is the opinion of Market-Pulse.com ("MP") and is intended to be used strictly for informational purposes. You should be aware that MP attempts to assure itself of the accuracy of the information contained in the analyses it publishes. In this regard, MP does, at times, rely on the accuracy of information supplied to it by the companies which are the subject of MP's analyses and/or parties related to those companies. MP also relies on the accuracy and integrity of information that is contained in company press releases and reports filed with the SEC. The companies mentioned in this publication have not approved the content or timing of the information being published unless otherwise noted.

MP, because it relies on information supplied by various third parties disclaims any responsibility for the accuracy of such information. Any investor considering making an investment in any security which has been the subject of a MP analysis or opinion should, before making any such investment, consult with his/her market professional and/or do his/her own independent research regarding the company which is the subject of an MP opinion, recommendation or analysis. Information regarding companies which MP has opined upon is normally available from many sources including the subject company's filings with the SEC and various press releases issued by the company. You should be aware that MP is often compensated for issuing analyses, recommendations or opinions concerning particular companies. Its opinion is therefore not unbiased and you should consider this factor when evaluating MP's statements regarding a company. MP has been compensated two hundred twenty five thousand dollars from DNAPrint Genomics, Inc. MP was also compensated four million restricted shares of common stock directly from DNAPrint Genomics, Inc. In addition, MP has two million restricted shares of common stock pending directly from DNAPrint Genomics, Inc. MP's officers and directors reserve the right to buy additional shares of the companies discussed in this opinion and may profit in the event those shares rise in value. When MP receives free trading shares as compensation for a profiled company, MP may sell part or all of any such shares during the period in which MP is performing such services. Market-Pulse.com and Market Pulse Breaking News Alert are owned by Market Pulse LLC.

Contact Information